SCHEMBL5452292

SCHEMBL5452292

COc1cccc2c(C(=O)NCc3cccc(C)c3)cn(CCCN3CCC(CCOc4ccccc4)CC3)c12

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 7/20 0.46
PTPN7 P35236 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CXCR4 P61073 1/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CCR3 P51677 2/20 0.42
HTR7 P34969 1/20 0.41
HTR2A P28223 1/20 0.41
POLB P06746 1/20 0.41
DRD2 P14416 1/20 0.41
DRD4 P21917 1/20 0.41
PDE10A Q9Y233 1/20 0.40
MAOA P21397 1/20 0.40
ACHE P22303 1/20 0.40
MAOB P27338 1/20 0.40
CHRM4 P08173 1/20 0.40
CNR1 P21554 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5444353 0.94 CNR2 (0.44) CNR2MEN1KMT2ACXCR4KDM4E
SCHEMBL5448697 0.93 PDE10A (0.48) CNR2PTPN7MEN1KMT2AKDM4E
SCHEMBL5463119 0.92 PTPN7 (0.42) CNR2PTPN7CCR3HTR7POLB
SCHEMBL5451967 0.92 CNR2 (0.50) CNR2PTPN7DRD2DRD4PDE10A
SCHEMBL5448753 0.91 CNR2 (0.49) CNR2PTPN7DRD2DRD4PDE10A
SCHEMBL5446497 0.90 CNR2 (0.45) CNR2PTPN7MEN1KMT2AKDM4E
SCHEMBL5455263 0.90 CNR2 (0.48) CNR2PTPN7KMT2AKDM4EALDH1A1
SCHEMBL5446893 0.89 CNR2 (0.46) CNR2PTPN7MEN1KMT2AHTR7
SCHEMBL5470088 0.89 CNR2 (0.48) CNR2PTPN7DRD2DRD4PDE10A
SCHEMBL5448700 0.89 CNR2 (0.54) CNR2CXCR4PDE10ACNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF ACADIA PHARMACEUTICALS INC. (US) 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213359-A1 BICYCLIC-NITROGEN COMPOUNDS AS MODULATORS OF GHRELIN RECEPTOR AND USES THEREOF GIPR, GHSR, GHRHR CNR2 106/4885PTPN7 592/4885MEN1 2039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.